Upload
bethanie-julianna-powers
View
222
Download
4
Embed Size (px)
Citation preview
NIAID Funding Opportunities in HIV/AIDS
ResearchKarl Salzwedel
Division of AIDS, NIAID, NIH
July 2, 2013
NIAID conducts and supports basic and applied research to better understand, treat, and ultimately
prevent infectious, immunologic, and allergic diseases.
The Division of AIDS (DAIDS)
Scientific Programs
• Basic Sciences Program• Therapeutics Research Program• Prevention Sciences Program• Vaccine Research Program
Steps Along the HIV Cure Pathway
Basic Research
Translational Research
Pilot Clinical Studies
Phase I-IV
Clinical Trials
Delivering Therapeutics to Residual Active HIV Reservoirs RFA (R01)
Martin Delaney Collaboratory: Towards an HIV-1 Cure (U19)
Beyond HAART: Innovative Therapies to Control HIV-1 (P01)
Targeting Persistent HIV Reservoirs (TaPHIR) PAR (R21/R33)
Clinical Trials Networks: Cure Agenda (UM1)
FY11
FY14
FY13
FY12
FY14
Basic Research
Translational Research
Pilot Clinical Studies
Phase I-IV
Clinical Trials
Targeting Latently Infected Cells Without Reactivation (R01)
Beyond HAART II Innovative Therapies to Control HIV (U19)
Pilot Clinical Trials to Eliminate the Latent
Reservoir (U01)
Quantitative Viral Outgrowth Assay (Q-VOA) Service Resource (N01)
Innovative Assays to Quantify the Latent HIV Reservoir (R21, R01)
Delivering Therapeutics to Residual Active HIV Reservoirs RFA (R01)
Martin Delaney Collaboratory: Towards an HIV-1 Cure (U19)
Beyond HAART: Innovative Therapies to Control HIV-1 (P01)
Targeting Persistent HIV Reservoirs (TaPHIR) PAR (R21/R33)
Clinical Trials Networks: Cure Agenda (UM1)
New
New
NewNew
New
New Funding Initiatives for 2015
NIH AIDS Reagent Program
• Viruses• Cell lines, hybridomas• Monoclonal and polyclonal antibodies• DNA clones, DNA libraries, expression vectors • Recombinant proteins, synthetic peptides• Reference panels for:
– PCR– HIV subtyping– Drug resistant viruses– Neutralizing antibodies and sera
• Antiviral drug standards
http://www.aidsreagents.org
Provides standardized reagents and new technologies to the AIDS research community
U.S. institutions with funding to provide shared infrastructure support for HIV research
CFARs support a multidisciplinary, collaborative environment that promotes basic, clinical, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS.
Web site: www.niaid.nih.gov/LabsAndResources/resources/cfar
CFAROne mission of the CFAR is to strengthen capacity for HIV/AIDS research in developing countries.
CFARs accomplish this through a variety of ways including:
• Establishment of Cores abroad which provide training, services and expertise to local investigators
• Provide funding for pilot projects with an international component through the CFAR Developmental Core
• Offer training/mentorship in-country or in US
• Access to databases, repositories, computer-based training
CFARs are a Trans-NIH Program
Co-funded by nine NIH Institutes:
National Institute of Allergy and Infectious Diseases (NIAID)National Cancer Institute (NCI)National Institute of Child Health and Human Development (NICHD)National Heart, Lung and Blood Institute (NHLBI)National Institute on Drug Abuse (NIDA)National Institute on Mental Health (NIMH)National Institute on Aging (NIA)National Institute of General Medical Sciences (NIGMS)National Institute of Nursing Research (NINR)
Co-managed by the NIH Institutes above, and by:
Office of AIDS Research (OAR)Fogarty International Center (FIC)
CENTERS FOR AIDS RESEARCH
CFAR projects funded 2009-2012
India (5)
China (4)
Peru (3)
Brazil (1)
Tanzania (11)
South Africa (20)
Zambia (5)
CFAR-Funded International HIV/AIDS Research
Malawi (8)
Kenya (26)
Cameroon (1)
Uganda (12)
Botswana (10)
Mexico (4)
Updated June 2012
Cambodia (1)
Zimbabwe (2)
Mozambique (4)
Namibia (2)
Rwanda (4)
Russia (1)
Canada (1)
Democratic Republic of Congo (1)
Ethiopia (1)Ghana (2)
Guatemala (1)
Haiti (1)
Romania (1)
Australia (2)
www.cnihr.org
Creative and Novel Ideas in HIV Research (CNIHR)Encouraging Innovation in HIV Research
Goal: to attract both international and U.S.-based early stage investigators from outside the field of HIV research
Up to 2 yrs, $150k per year Direct Costs
Concept sheets (2 pages) will be submitted by October 16, 2013
These are U01, collaborative grants, which establish international
regional centersFoster collaboration on HIV research on
regional and global levelAdvance methodology for collection
and harmonization of dataAddress research questions using data
sets
Region 1: North America
Region 2: Latin America & Caribbean (CCASAnet)
Region 5: Australia, China, India, Pakistan, Asia (excluding Central Asia)
Region 10: East AfricaRegion 11: South AfricaRegion 9: Central AfricaRegion 8: West Africa
7 Funded Regions
International Research in Infectious Diseases including AIDS (IRIDA) Program (R01)
Objective: to advance the development of local scientific expertise, build local research infrastructure, and to increase collaborative research partnerships at
resource limited eligible foreign countries that propose research related to infectious diseases that are of interest to that country
Application Receipt Date for AIDS Applications:August 23, 2013
Contact (for HIV/AIDS Research):
Opendra Sharma, Ph.D.Telephone: (301) 496-9041
Email: [email protected]
http://grants.nih.gov/grants/guide/pa-files/PAR-11-145.html
PAR-11-145
In Summary
There are many opportunities − researching the best fit for what you wish to do is critical.
Karl Salzwedel, [email protected] Diana Finzi, [email protected] Ann Namkung Lee, [email protected]
National Institute of Mental HealthDivision of AIDS Research
Research PrioritiesDianne Rausch, Ph.D.
NIH Grantsmanship WorkshopInternational AIDS Society Meeting
Kuala Lumpur, MalaysiaJuly 2, 2013
NIMH RESEARCH AREAS
Behavioral Science
Develop, test, and implement interventions to prevent the spread of
HIV infection through behavior change and
improve health outcomes
Basic Neuroscience
Identify mechanisms underlying HIV-induced
CNS dysfunction, and develop therapeutic
strategies to prevent and treat them
HIV Behavioral Science: Research Priorities
Combination prevention interventions Feasible and cost-effective interventions “Test and Treat” research questions Prevention among MSM Behavioral aspects of biomedical tools Implementation science, especially in
collaboration with existing platforms (e.g., CDC services, PEPFAR sites)
HIV Basic Neuroscience: Research Priorities
• Biomarkers linked with mechanisms of neuropathogenesis
• Impact of aging and co-morbidities on HIV/CNS disease
• Role of global clade diversity and host genetic factors
• Develop novel therapeutics targeting HIV
neuropathogenesis
• New approaches for eradication of HIV/CNS reservoirs
• Moving NeuroAIDS therapies to the clinic
NIMH AIDS RESEARCH INITIATIVES
RFA: Pathophysiology of HIV-Associated Neuro-degeneration in Aging Populations on Long-Term ART
RFA: Eradication of HIV-1 from CNS Reservoirs
PAR: Novel NeuroAIDS Therapeutics RFA: Behavioral Mechanisms in Biomedical Strategies to Prevent HIV
Infections
RFA: Reinvigorating HIV Prevention for Men who have Sex with Men
RFA: Advancing Community-level Approaches to Reduce HIV
RFA: Promoting Engagement in Care and Timely ART Initiation
RFA: Assessing the Role of Stigma in HIV Prevention and Care
National Cancer Institute HIV/AIDS Cancer
Programs
Mostafa Nokta, MD Ph.D.
Director, AIDS Cancer Clinical Program
Office of HIV and AIDS Malignancy
National Cancer Institute
IAS Kuala Lumpur, July 2, 2013
Nati
onal
Can
cer I
nstit
ute
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
HIV/AIDS Research in the NCI
• The NCI conducts substantial extramural and intramural research programs focused on HIV-associated malignancies.
• These programs include epidemiology, basic science, translational science, and clinical research.
• The NCI is currently expanding the international focus of these efforts.
• The NCI also conducts intramural research on HIV infection.
Cancers in HIV Disease
AIDS-Defining Virus Kaposi’s Sarcoma HHV-8 Non-Hodgkin’s Lymphoma EBV, HHV-8
(systemic and CNS) Invasive Cervical Carcinoma HPVNon-AIDS Defining Anal Cancer HPV Hodgkin’s Disease EBV Lung Leiomyosarcoma (pediatric) EBV Hepatoma HBV, HCV
Non-AIDS Defining Cancers that are Increased in People with AIDS
Cancer SIR 95% CIAnus 19.6 (14.2-79.9)Hodgkin's lymphoma 13.6 (10.6-17.1)Penis 8.0 (2.2-20.6)Other/unknown site 3.4 (2.5-4.4)Liver 3.3 (2.0-5.1)Larynx 2.7 (1.6-4.4)Lung 2.6 (2.1-3.1)Myeloma 2.2 (1.1-3.9)Myeloid and monocytic leukemia 2.2 (1.1-4.0)Oral cavity and pharynx 2.1 (1.4-3.0)Renal cell carcinoma 1.9 (1.1-3.2)Kidney and renal pelvis 1.8 (1.1-2.8)All non-AIDS asociated cancers 1.7 (1.6-1.9)
- United States, 1996-2002
Source: Engles et al., AIDS, 2006, 20, 1645-54
AIDS Malignancy Consortium (AMC)
Evaluate clinical interventions for the treatment and prevention of malignancies in people with HIV
Investigate the biology of these malignancies in the context of clinical trials
Conduct Phase I, II and III clinical trials Address issues of international importance in HIV
associated malignancies Contribute specimens and clinical data to the
ACSR
AMC Clinical Sites
Core sitesAffiliated sites
AMC International Sites
Kampala, UgandaEldoret, Kenya
Lilongwe, MalawiHarare, Zimbabwe
Johannesburg South Africa
Abuja, Nigeria
MumbaiChennai
Sao Paolo, Brazil
Core SitesCollaborative Sites
AMC International Objectives
Assist with capacity building in developing nations for HIV-related cancers
Develop AMC-sponsored and co-sponsored collaborative studies with emphasis on trials that:
- Employ hypothesis-driven, scientifically sound, locally relevant and feasible therapies
- Address important pathogenesis-based questions - Utilize the unique scientific expertise of the AMC
Susan Krown, MD , [email protected] Nokta, MD, PhD, [email protected]
AIDS and Cancer Specimen Resource
• Provide high-quality HIV-associated malignancy specimens to qualified investigators at little or no cost.• Types of specimens: Frozen tissues, PBMCs, plasma, body fluids (e.g., saliva, urine, CSF), formalin-fixed tissues.• Special Collections: TMAs (NHL, KS) AMC studies, WIHS Study,HIV multi-site autopsies, international collections.
AIDS-related lymphoma, one of the tumors used to make the tissue microarray (TMA) shown in the insert.
ACSR Collaborations
• Aim : compare and contrast the genomic alterations of tumors in HIV+ patients and in HIV- patients.
• Present list of tumors included– DLCBL– BL– Lung Cancer– Anal/Cervical Cancer– Hepatocellular carcinoma (HCC)
The HIV+ Tumor Molecular Characterization Project (HTMCP):
Sites of Research Training Awards in HIV-Associated Malignancies
Zambia
South Africa
Uganda (2)
KenyaRwanda
Cameroon
Nigeria
Tanzania
• Nigeria/UM: Clinical trials, cancer epidemiology and cancer registration
• Rwanda/Einstein: Clinical research of HPV and AIDS-associated malignancies
• Tanzania/Duke: Clinical and laboratory research methodology, pathology and radiology in HIV-associated malignancies
• Uganda/UW: Clinical trials and cancer epidemiology of HIV-associated malignancies
• Uganda/UCSF: Kaposi’s sarcoma epidemiology, early detection and clinical intervention
• South Africa/Columbia: Clinical studies of Kaposi sarcoma, non-Hodgkin lymphoma and cervical cancer
• Cameroon/NYU: Basic laboratory research in HIV/AIDS cancers
• Zambia/UA: Prevention and treatment of cervical cancer
• Kenya/West Virginia: Clinical studies of HIIV-related malignancies Geraldina Dominguez, PhD
Comprehensive Cancer Centers
Cancer Centers
Planning Centers
Cancer Centers
Dr. Hasnaa [email protected]
NCI Partnerships in Trans-NIH AIDS Initiatives
• NIAID Led– Centers for AIDS Research (CFAR)
• Inter-CFAR HIV/AIDS Related Malignancy Working Group (iCHARM) and additional supplements linking Cancer Centers and CFARs FY2008-2012
– Women’s Interagency HIV Study (WIHS)• Cervical disease and progression• AIDS-malignancy tracking within cohort
– Multicenter AIDS Cohort Study (MACS)• Anal disease and progression and • Study of biomarkers for AIDS-related lymphoma risk
– International epidemiological Databases to Evaluate AIDS (IeDEA)• Tracking of AIDS-related malignancies
• FIC Led– AIDS International Training and Research Program (AITRP)
• Additional supplements FY2008-2012
CFAR Map
Dr. Geraldina [email protected]
Funding Opportunities (Cont.)
• Cancer Prevention Research Small Grant Program (R03) http://grants.nih.gov/grants/guide/pa-files/PAR-11-079.html
• Current and Recent Program Announcements (PAs)http://deais.nci.nih.gov/Public/RFA-PA.jsp?nt=P
NIH/NCI Sponsored Training Programs
• Short Term Exchange Program, CGH/NCI Visiting Fellows & Visiting Scientists train with
Intramural and NCI-supported Extramural Scientists
http://www.cancer.gov/aboutnci/globalhealth/programs-activities/stsep
LMI Countries
Dr. Ben Prickril, [email protected]
• NCI Summer Curriculum in Cancer Preventionhttps://cpfp.cancer.gov/summer/summer.php
Registration open November 15, 2013
All Countries
http://oham.cancer.gov
International Clinical Trials Portalwww.cancer.gov/clinicaltrials/international
• Web-based “tool box” for international cancer researchers
• Focus on collaboration between NCI and investigators outside the U.S.
More Information can be found at: http://oham.cancer.gov/
November 12-13, 2013 Lister Hill Center Auditorium
National Institutes of Health in Bethesda, Maryland
Presented by the Office of HIV and AIDS Malignancy (OHAM) National Cancer Institute
Topics will include viral oncology, immunology, genetics, epidemiology, pathogenesis, early diagnosis, and clinical
investigation of malignant diseases associated with HIV and other acquired immunodeficiency states.
ABSTRACT DEALINE is AUGUST 31, 2013
14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)